Application of thymidine derivative in preparation of drugs

2:

• The method according to claim 1, wherein said thymidine derivative comprises a structure of Formula (I), or a pharmaceutically acceptable salt, solvent, hydrate, prodrug form and stereoisomer thereof:
• wherein R2, R3, R4, R5, R6 and R7 are not simultaneously hydrogen.

4:

• The method according to claim 2, wherein R6 is hydrogen.

5:

• The method according to claim 2, wherein R6 is
• wherein said R61 is C1-C6 alkyl.

6:

• The method according to claim 2, wherein any one of R2 and R3 is independently
• wherein M1 is oxygen or sulfur, and R8 comprises one or more groups selected from the group consisting of hydrogen, substituted or unsubstituted hydroxyl, substituted or unsubstituted sulfhydryl, substituted or unsubstituted amino, substituted or unsubstituted C1-C5 alkyl, substituted or unsubstituted C1-C5 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted aralkyl;
• M2 is silicon or carbon, and R9 comprises a group selected from the group consisting of hydrogen, substituted or unsubstituted hydroxyl, substituted or unsubstituted sulfhydryl, substituted or unsubstituted amino, substituted or unsubstituted C1-C5 alkyl, substituted or unsubstituted C1-C5 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted aralkyl, R9 is selected from the group consisting of C1-C5 alkyl, C1-C5 cycloalkyl, phenyl or benzyl.

7-13. (canceled)

14:

• The method according to claim 2, wherein R3 is hydrogen.

15:

• The method according to claim 2, wherein R4 is hydrogen.

16:

• The method according to claim 2, wherein R5 is hydrogen.

(canceled)

18:

• The method according to claim 1, wherein said thymidine derivative is one or more selected from the group consisting of:

19:

• The method according to claim 1, wherein said thymidine derivative comprises a structure of Formula (II):
• wherein at least one of R1 and R2 comprises a non-steroidal anti-inflammatory drug (NSAID) moiety.

20:

• The method according to claim 19, wherein said NSAID moiety comprises salicylic acid or a derivative thereof, aryl acetic acid or a derivative thereof, heteroaryl acetic acid or a derivative thereof, indoleacetic acid or a derivative thereof, indene acetic acid or a derivative thereof, anthranilic acid or a derivative thereof and/or enolic acid or a derivative thereof.

(canceled)

22:

• The method according to claim 19, wherein R1 is any one group selected from the group consisting of:
• and R2 is hydrogen.

23:

• The method according to claim 19, wherein R2 is any one group selected from the group consisting of:
• and R1 is hydrogen.

(canceled)

25:

• The method according to claim 19, wherein said thymidine derivative is one or more selected from the group consisting of:

(canceled)

27:

• The method according to claim 1, wherein said chemotherapeutical drug comprises a pyrimidine nucleoside analog or a prodrug thereof.

28-30. (canceled)

31:

• The method according to claim 1, wherein said disease or disorder associated with administration of the chemotherapeutical drug comprises skin tissue disease or disorder associated with administration of the chemotherapeutical drug, hemopoietic tissue disease or disorder associated with administration of the chemotherapeutical drug, limb disease or disorder associated with administration of the chemotherapeutical drug, cardiac disease or disorder associated with administration of the chemotherapeutical drug, nervous system disease or disorder associated with administration of the chemotherapeutical drug, facial feature disease or disorder associated with administration of the chemotherapeutical drug and/or gastrointestinal disease or disorder associated with administration of the chemotherapeutical drug.

32-34. (canceled)

35:

• The method according to claim 1, wherein said disease or disorder associated with administration of the chemotherapeutical drug comprises hand-foot syndrome associated with administration of the chemotherapeutical drug and/or diarrhea associated with administration of the chemotherapeutical drug.

36-47. (canceled)

48:

• A pharmaceutical combination or a kit, comprising:
• 1) a chemotherapeutical drug;
• and 2) the thymidine derivative of claim 1.

49-53. (canceled)

54:

• A method of preventing or treating a disease or disorder associated with administration of a chemotherapeutical drug in a subject, comprising administering a combination of a thymidine derivative and an uridine derivate to said subject, wherein said thymidine derivative comprises a structure of Formula (I):
• wherein R2, R3, R4, R5, R6 and R7 are not simultaneously hydrogen.

55-127. (canceled)